<DOC>
	<DOCNO>NCT00642057</DOCNO>
	<brief_summary>Although result study look tetrabenazine show effectiveness management hyperkinetic ( much ) movement disorder , make available U.S . The drug must obtain Cambridge Laboratories , distributor , use individual IND ( # 16,161 ) . The cost drug pass patient . The purpose protocol provide efficacious drug , side effect , attempt get rid variety incapacitate dyskinesia ( abnormal movement ) .</brief_summary>
	<brief_title>Compassionate Use Tetrabenazine Treatment Abnormal Movements</brief_title>
	<detailed_description>The purpose protocol provide compassionate use efficacious drug , side effect , attempt get rid variety incapacitate dyskinesia ( abnormal movement ) .</detailed_description>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Tetrabenazine</mesh_term>
	<criteria>Subjects evaluate Baylor PDCMDC demonstrate need tetrabenazine treatment . Willing sign inform consent . Willing comply procedure require part study . Those subject unwilling comply study requirement . Subjects unable give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>chorea</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>hyperkinetic</keyword>
</DOC>